Unicycive Therapeutics (UNCY) CEO receives 762,200 restricted stock units award

Rhea-AI Filing Summary

Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics, Inc. reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units. These RSUs are payable solely in common stock and vest in three equal installments on each anniversary of the grant date over three years, conditioned on his continued service with the company. Following this grant, Gupta is reported as holding 762,200 RSUs tied to an equal number of underlying common shares.

Insights

Executive compensation and governance analyst

CEO receives a multi-year RSU grant, typical equity-based compensation.

The CEO of Unicycive Therapeutics, Shalabh K. Gupta, was granted 762,200 restricted stock units, each tied to one share of common stock and granted at a price of $0.00 per unit. This is classified as a grant or award, not a market purchase.

The RSUs vest in three annual installments, each covering 1/3 of the grant, starting on the first anniversary of the grant date, and require continued service with the company. Such service-based vesting aligns management incentives with long-term company performance and retention but does not itself indicate a directional view on the stock.

Because this is a compensation award rather than an open-market trade, its informational value for short-term sentiment is limited. Future company filings may detail additional grants or changes in Gupta’s overall equity position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gupta Shalabh K.

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	762,200	$0.00	--

Holdings After Transaction: Restricted Stock Units — 762,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 762,200 units Grant price per RSU: $0.00 per unit Underlying common shares: 762,200 shares +2 more

5 metrics

RSUs granted 762,200 units Restricted stock units granted to CEO on May 14, 2026

Grant price per RSU $0.00 per unit Compensation award, not a market purchase

Underlying common shares 762,200 shares Each RSU corresponds to one share of common stock

RSUs after transaction 762,200 units Total RSUs reported following the grant

Vesting schedule 1/3 per year for 3 years Annual vesting on each grant date anniversary, service-based

Key Terms

Restricted Stock Units, RSU Award, vesting, continued service

4 terms

Restricted Stock Units financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU Award financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock"

vesting financial

"The shares subject to the RSU award vest 1/3 on the anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued service financial

"for 3 years, subject to the Reporting Person's continued service with the Issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gupta Shalabh K.

(Last) (First) (Middle)

C/O UNICYCIVE THERAPEUTICS, INC.

1975 W. EL CAMINO REAL SUITE 204

(Street)

MOUNTAIN VIEW CALIFORNIA 94040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	05/14/2026		A		762,200		(1)	(1)	Common Stock	762,200	$0	762,200	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer.

	/s/ Shalabh Gupta	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity award did Unicycive Therapeutics (UNCY) grant to its CEO?

Unicycive Therapeutics granted CEO Shalabh K. Gupta 762,200 restricted stock units. Each RSU is payable in one share of common stock, providing equity-based compensation that links his potential future payout to the company’s share performance over time.

How do the 762,200 RSUs granted to UNCY’s CEO vest?

The 762,200 RSUs vest in three equal installments, with one-third vesting on each anniversary of the grant date for three years. Vesting is conditioned on the CEO’s continued service with Unicycive Therapeutics throughout the vesting period.

Is the Unicycive Therapeutics CEO’s RSU grant a market purchase of UNCY stock?

No, the CEO’s 762,200 restricted stock units represent a grant or award, not a market purchase. The RSUs were issued at a price of $0.00 per unit as part of his compensation, rather than being bought on the open market.

What does the Form 4 for UNCY show about post-grant RSU holdings?

After the reported transaction, the Form 4 shows CEO Shalabh K. Gupta holding 762,200 restricted stock units. Each RSU corresponds to one underlying share of common stock, reflecting his potential future equity stake if all units ultimately vest.

What conditions apply to the RSU award granted by Unicycive Therapeutics?

The RSU award vests one-third each year on the grant’s anniversaries and is subject to the CEO’s continued service with Unicycive Therapeutics. If service ceases before vesting dates, unvested RSUs may not be earned, depending on plan terms.